BioNTech Says 'No Evidence' Its Jabs Need Adapting For COVID-19 Variants

"To date, there is no evidence that an adaptation of BioNTech's current Covid-19 vaccine against key identified emerging variants is necessary," the company said in a statement.

German firm BioNTech said Monday that the Covid-19 vaccine it developed with Pfizer does not require any modifications at the moment to protect against variants of the virus. "To date, there is no evidence that an adaptation of BioNTech's current Covid-19 vaccine against key identified emerging variants is necessary," the company said in a statement. Nevertheless, in preparations for a need at some point to make tweaks to its current vaccine, the company said it began tests in March on a "modified, variant-specific version" of its jabs. "The aim of this study is to explore the regulatory pathway that BioNTech and Pfizer would pursue if SARS-CoV-2 were to change enough to require an updated vaccine," it said.